Familial Chylomicronemia Syndrome

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.

The FDA approved Tryngolza for the treatment of adults with familial chylomicronemia syndrome when used in combination with an appropriate low-fat diet, according to an Ionis Pharmaceutical press release.

The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

Monthly olezarsen 80 mg significantly lowered triglyceride levels and also reduced incidence of acute pancreatitis vs. placebo in patients with familial chylomicronemia syndrome, according to a study in The New England Journal of Medicine.

ATLANTA — In this Healio video exclusive, Seth S. Martin, MD, MHS, FAHA, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining the Balance study on familial chylomicronemia syndrome.

ATLANTA — Plozasiran provided sustained reduction in triglycerides, apolipoprotein C-III and remnant cholesterol out to 48 weeks for patients with severe hypertriglyceridemia, a speaker reported.

The FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen, an investigational ligand-conjugated antisense drug for the treatment of familial chylomicronemia syndrome, according to a company release.

BOSTON — After years of failed clinical trials with agents to lower severely elevated triglycerides, emerging therapeutics hold promise for effectively addressing hypertriglyceridemia and reducing associated CV risks, a speaker reported.